HARP: רווח נקי למניה (EPS TTM) Harpoon Tx

Integration into the Merck structure at a premium and the success of the TriTAC platform in treating lung cancer define the financial profile of Harpoon Therapeutics (HARP). The change in the rolling annual EPS clearly demonstrates this trend, where -8.74 becomes the new value for the indicator. A stable liquidity reserve supports the development of targeted drugs, although geopolitical tensions and sanctions complicate the logistics of biomaterials, slowing down global certification.

Amidst fierce competition for patients and patent wars within the T-cell immunotherapy sector, this metric allows for an assessment of the financial stability of Harpoon Therapeutics (HARP). Net income per share over the last four quarters is calculated by dividing the total annual net income by the number of securities. This indicator demonstrates the actual efficiency of the business, stripped of the impact of issuance. Positive dynamics confirm management's ability to withstand the expansion of mRNA therapy, while a decline in the indicator signals a risk of capital freeze.